LEGN241220P20000
- 0.05
- 0.000.00%
Legend Biotech Newsroom
Legend Biotech (LEGN) Gets a Buy From RBC Capital
Morgan Stanley Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $82
Morgan Stanley Remains a Buy on Legend Biotech (LEGN)
Truist Financial Maintains Legend Biotech(LEGN.US) With Buy Rating
Legend Biotech (LEGN) Gets a Buy From Truist Financial
Cantor Fitzgerald Maintains Legend Biotech(LEGN.US) With Buy Rating, Raises Target Price to $83
Scotiabank Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $76
Legend Biotech Analyst Ratings
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $73 to $94
Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (TCRX), Legend Biotech (LEGN) and ICU Medical (ICUI)
Legend Biotech (LEGN) Gets a Hold From William Blair
Truist Financial Maintains Legend Biotech(LEGN.US) With Buy Rating
Truist Financial Sticks to Their Buy Rating for Legend Biotech (LEGN)
Legend Biotech Analyst Ratings
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $86
Analysts Have Conflicting Sentiments on These Healthcare Companies: Legend Biotech (LEGN), Molina Healthcare (MOH) and Edwards Lifesciences (EW)
Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $94
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
Strategic Growth and Promising Prospects Drive Buy Rating for Legend Biotech
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $73